However, Zydus is not immune to the recent industry-wide US business pressures. Its US sales, which contributed 40% to revenues in the June quarter (Q1FY27), declined year-on-year for the second straight quarter. Weighed down by a higher base from large gRevlimid contribution, competition and price pressures, it registered a 12% constant-currency drop in Q1FY27.
